Rapport Therapeutics RAPP 深 滬
等待開盤 11-04 09:30:00 美东时间
25.44
+0.310
+1.23%
華盛通- 最 高26.06
- 今 開25.39
- 成交量 82.35万股
- 最 低 25.13
- 昨 收 25.13
- 總市值 14.33亿
- 52周最高 52.93
- 市盈率 靜 --
- 換手率 1.46%
- 52周最低 22.061
- 委 比 73.72%
- 總股本 5631.16万
- 歷史最高 52.93
- 量 比 0.34
- 振 幅 3.70%
- 歷史最低 6.43
- 每 手 1
- 風險率 6.98%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Rapport Therapeutics to Participate in Upcoming Investor Conferences
Rapport Therapeutics announced that its management will participate in two upcoming investor conferences: the Stifel 2026 Healthcare Conference in New York City on November 11, 2026, and the Jefferies Global Healthcare Conference in London on November 16, 2026. The events will include fireside chats and a company presentation, with live webcasts available on the company's website. Rapport focuses on developing small molecule precision medicines f...
11-03 12:00
Rapport Therapeutics收涨0.32%，成交额3312.79万美元
11月3日，Rapport Therapeutics（RAPP）收涨0.32%，报25.13美元，成交额3312.79万美元，市值12.06亿美元。 行情数据...
11-03 06:39
Rapport Therapeutics (RAPP) Shares Sink 20% After Hours
Rapport Therapeutics Inc. (NASDAQ: RAPP) shares fell 20.04% to $22.02 in after-hours trading Tuesday. Rapport Therapeutics is a clinical-stage biotechnology company developing small-molecule precision medicines for neurological and psychiatric disorders. Proposed Stock And Convertible Notes Offering...
10-28 15:01
Rapport Therapeutics Commences Separate Underwritten Public Offerings Of $200M Of Shares And $150M Aggregate Principal Amount Of Convertible Senior Notes Due 2032
Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it has commenced separate under...
10-28 04:35
Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement
Rapport Therapeutics宣布启动2.00亿美元的普通股和1.50亿美元的2032年到期可转换债券的发行，同时授予承销商额外购买3000万美元股票和2250万美元债券的权利。公司计划将资金用于临床试验、研发和一般企业用途。债券利率和转换率尚未确定，债券可转换为股票，且在特定情况下可被赎回或回购。公司还计划进行一次私募，与普通股发行同时进行。
10-27 20:32
Rapport Therapeutics收跌2.26%，成交额3091.32万美元
10月24日，Rapport Therapeutics（RAPP）收跌2.26%，报25.93美元，成交额3091.32万美元，市值12.44亿美元。 行情数据...
10-24 05:42
美股前瞻 | AI交易熄火，中东局势恶化！纳指期货盘前跌逾1.6%；特斯拉绩后一度跌逾5%，财报未能“打动”市场！
AI交易熄火，中东局势恶化！纳指期货盘前跌逾1.6%；业绩股盘前齐挫！特斯拉绩后一度跌逾5%，Meta跌逾2%；小摩逆势力挺：股市暴跌可能已接近尾声！>>
10-22 20:22
美股前瞻 | 绩优股盘前飙涨！SpaceX一度升逾10%，AI营收暴增830%；特斯拉、Meta盘后放榜！
绩优股盘前飙涨！SpaceX一度升逾10%，AI营收暴增830%；特斯拉、Meta盘后放榜！木头姐指特斯拉有望涨至5000美元；戴尔预警：明年内存短缺将进一步恶化！>>
10-21 20:21
Analysts’ Top NA Picks: Rapport Therapeutics, Inc. (RAPP), SpaceX (SPCX)
There’s a lot to be optimistic about in the NA sector as 3 analysts just weighe...
10-21 18:50
Why Is Rapport Therapeutics Stock Trading Higher Today?
Rapport Therapeutics Inc. (NASDAQ:RAPP) stock is trading higher on Tuesday with a premarket session volume of 1.439 million versus the average volume of 351.078 thousand, according to Benzinga Pro data. The company shared positive topline results from its Phase 2 clinical trial evaluating RAP-219 in...
10-20 21:31
